About Mary Ann Chirba
Mary Ann Chirba holds a bachelor's degree in biology from Colgate University and a J.D., magna cum laude, from Boston College Law School. She holds a Doctorate of Science in Health Policy and Law as well as a Master's in Public Health from the Harvard School of Public Health. She is the lead author of Health Care Reform: Law and Practice - A Comprehensive Guide to the Affordable Care Act and its Implementing Regulations, a 2 volume treatise, co-authored by Alice A. Noble (who also teaches at the Law School) and Michael M. Maddigan, and published by Lexis Nexis/Matthew Bender.
Since 1984, Professor Chirba has taught a variety of courses at Boston College Law School, including Law Practice I and II, Legal Reasoning Research & Writing, Federal Health Reform: The Affordable Care Act, Comparative Health Law, Health Care Law and Policy I & II, Advocacy Writing, Advanced Legal Writing, and Product Liability Law. She is a full Professor of Legal Reasoning and a member of the Law School’s health law faculty.
Professor Chirba holds a joint faculty appointment with the Tufts Medical School through its joint JD/MPH program with BC Law. She has lectured on a various health law issues at Harvard Medical School, Children's Hospital of Boston, and the Brandeis/Heller School. In past years, Professor Chirba has been an adjunct faculty member at the Harvard School of Public Health, where she taught courses on Pharmaceutical Product Safety, Tobacco Regulation, Current Developments in Health Law, Managed Care Law & Regulation, and Medical Malpractice & Risk Management.
With Prof. Alice A. Noble, Dr. Chirba has published and spoken extensively on the Affordable Care Act. She has also published numerous articles and been invited to present at the World Stem Cell Summit and other domestic and international conferences on FDA and international regulation of adult stem cell therapies and regenerative medicine. Prof. Chirba serves as a member of the Advisory Boards of the International Federation of Adipose Therapeutics, the Cell Therapy Foundation, and the Leadership Education in Neuro-Developmental Disabilities (LEND) Fellowship program at Boston Children’s Hospital.
- Fall 2016: Law Practice 1
- Spring 2017: Law Practice II
Mary Ann Chirba
Professor of Legal Reasoning, Research & Writing
Boston College Law School
885 Centre Street
Newton, MA 02459
East Wing 413
Health Law and Policy (22)
FDA Regulation of Adult Stem Cell Therapies as Used in Sports Medicine Journal of Knee Surgery (2015)
In sports medicine, adult stem cells are the subject of great interest. Several uses of stem cells are under investigation including cartilage repair, meniscal regeneration, anterior cruciate ligament reconstruction, and tendinopathy. Extensive clinical and basic ...
Our Bodies, Our Cells: FDA Regulation of Autologous Adult Stem Cell Therapies Bill of Health (2013)
Stem cells have been an endless source of fascination and controversy since Dolly the sheep was cloned in 1996. This month’s announcement of a cloned human embryo from a single skin cell came on the ...
The ACA’s Tobacco Use Rating: Implementation, Inconsistencies and Ironies HealthLawProf Blog (2013)
As the Affordable Care Act continues toward full implementation, the law’s complexity is on full display. As we have noted in earlier writings, the ACA continues the federal tradition of using a fragmented approach to ...
Medical Malpractice, the Affordable Care Act and State Provider Shield Laws: More Myth than Necessity? Bill of Health (2013)
Given the ambitions and reach of the Affordable Care Act, confusion about its intended and inadvertent impact is inevitable. Since its enactment in 2010, the ACA has raised legitimate and less grounded concerns among various ...
Individual And Group Coverage Under The ACA: More Patches To The Federal-State Crazy Quilt Health Affairs Blog (2013)
From the introduction: Throughout the 2012 Presidential campaign, Republican contenders criticized the Affordable Care Act (ACA) as a “federal take-over of health care” for its promotion of national uniformity in health coverage and access. Yet ...
The Supreme Court Upholds The Individual Mandate: But Who Are We Talking About? Health Affairs Blog (2012)
From the introduction: While the Affordable Care Act’s individual mandate survived constitutional scrutiny in NFIB v. Sebelius, a Republican president and/or changes in the House or Senate this fall could lead to its demise. As ...
The Supreme Court On The Affordable Care Act: What We Are Waiting For Health Affairs Blog (2012)
From the introduction: With the U.S. Supreme Court poised to rule on the Affordable Care Act (ACA) it is worth reminding ourselves of what, exactly, we have been waiting for. We await a judicial opinion ...
ERISA Preemption of State “Play or Pay” Mandates: How PPACA Clouds an Already Confusing Picture Journal of Health Care Law & Policy (2010)
From the introduction: Although ERISA preemption was ranked among the top "eight pertinent issues" that needed to be addressed in order to achieve comprehensive health care reform, Congress opted to avoid it when it passed ...
Drawing Lines in Shifting Sands: The U.S. Supreme Court's Mixed Messages on ERISA Preemption Imperil Health Care Reform Journal of Legislation (2010)
This article explains how and why the U.S. Supreme Court’s increasingly erratic preemption jurisprudence has fueled a health care system that routinely harms patients, frustrates health care providers, and derails state reform efforts. It begins ...
An Uncertain Risk and an Uncertain Future: Assessing the Legal Implications of Mercury Amalgram Fillings. Health Matrix: Journal of Law-Medicine (2004)
Trying to buy a mercury thermometer at the local pharmacy these days will result in a deluge of information regarding the risks of mercury and the proper disposal protocol for mercury thermometers as hazardous waste. ...
Food and Drug Law (1)
A Decade’s Quest for Safer Drugs: Congressional Committee Green Lights Regulation of Drug Supply Chains and Compounding Manufacturers Bill of Health (2013)
On May 22. 2013, the Senate Health, Education, Labor and Pensions (HELP) Committee unanimously approved S.959, “The Pharmaceutical Compounding Quality and Accountability Act,” and S.957, “The Drug Supply and Security Act,” (now incorporated into S. ...